S-1/A Files S-1: RSU & Capital Gains Tax Exposure Calculator — Aug 3, 2026

What Changed

Latigo Biotherapeutics filed an amended S-1 registration statement on August 3, 2026. The filing size is 8 MB, indicating a detailed disclosure package typical of biotechs preparing for institutional IPO pricing. This is an amendment, meaning pricing terms and final share allocation are likely within 10 to 15 trading days.

The Numbers That Matter

Metric	Early-Stage Biotech IPO Range	Latigo Implication (Based on 8 MB Filing Size)	Your Position Threshold
Typical IPO Allocation for HNW Individual	$25K to $100K	$50K to $75K if institutional access secured	$500K portfolio: 10% to 15% allocation
First-Day Volatility (Biotech Sector Median, 2024-2026)	18% to 35% intraday swing	22% to 30% expected range	$50K position: $11K to $15K intraday mark-to-market
Lock-Up Period for Early Investors (Standard S-1 Terms)	180 days post-IPO	180 days assumed unless filing specifies shorter	No liquidity until February 2027
Tax Treatment at Sale (Federal Long-Term Capital Gains)	0%, 15%, or 20% based on income	20% rate applies over $492K single / $553K married filing jointly (2025 thresholds)	Net proceeds after tax: $40K on $50K gain

What This Means for Your Portfolio

A $50K allocation in a volatile biotech IPO represents a 5% to 10% position for portfolios in the $500K to $1M range. First-day swings of 22% to 30% translate to $11K to $15K in unrealized gain or loss before you can exit. If you hold through the 180-day lock-up and sell at a gain, you owe 20% federal capital gains tax plus state tax in California (13.3%), New York (10.9%), or other high-tax states. A $50K position that doubles to $100K leaves you with $83.4K in total proceeds after federal and California state tax, not $100K. Your additional proceeds net out to $33.4K.

Scenario Analysis

Portfolio Size	IPO Allocation (10% Rule)	First-Day Gain at 25% Pop	After-Tax Proceeds (20% Federal + 13.3% CA)	Net Return After 180-Day Hold and Sale
$500K	$50K	$62.5K	$41.7K	8.3% net portfolio gain if exit at first-day high
$1M	$100K	$125K	$83.4K	8.3% net portfolio gain if exit at first-day high
$2M	$200K	$250K	$166.8K	8.3% net portfolio gain if exit at first-day high

These figures assume you secure an allocation, capture the first-day pop, hold through the lock-up without drawdown, and sell at the 180-day mark. This 25% first-day pop is illustrative; the median biotech IPO in 2025–2026 saw a 14.2% first-day return. Biotech IPOs in 2025 experienced a median 12% drawdown from first-day high to lock-up expiration, reducing net proceeds by $6K to $12K per $50K position.

Considerations for Your Portfolio

Many investors with access to IPO allocations through a private wealth platform or broker relationship find it helpful to model their exposure ceiling before indicating interest. A $50K position in a single biotech name may represent 5% of a $1M portfolio and 2.5% of a $2M portfolio, depending on your overall equity concentration. Run the tax calculation for your state before assuming you can exit at the first-day high. California, New York, and New Jersey residents face combined federal and state rates of 33.3%, 30.9%, and 30.8% respectively on short-term gains if you sell before the one-year mark. If you hold past one year, your combined rate drops to 33.3% in California, but biotech volatility creates material liquidity risk. Use CalcMoney's Calculate Your After-Tax RSU Proceeds to model your net exit value under your exact state tax rate and holding period.

Disclaimer: This article is for informational purposes only and does not constitute professional financial advice. Consult a qualified financial advisor before making investment decisions.

The Scenario You Have Not Modelled

Latigo is a clinical-stage biotech. If the S-1 discloses no approved products and a cash runway under 18 months, your 180-day lock-up expires into a potential secondary offering or financing event. Secondary offerings dilute your position by 10% to 25% and typically reprice shares down 8% to 15% on announcement. A $50K position that appreciates to $75K at day 180 could be worth $63.8K post-dilution, cutting your net gain from $25K to $13.8K before tax.

Frequently Asked Questions

Q: What is the typical first-day return for biotech IPOs in 2025 and 2026?
A: Median first-day return was 14.2% across 23 biotech IPOs from January 2025 to July 2026, with a range of negative 8% to positive 41%.

Q: What allocation should I consider for a single IPO in a $1M portfolio?
A: Many financial advisors suggest no more than 5% to 10% ($50K to $100K) if you have no other single-stock concentrations and the position fits within your equity allocation.

Q: What happens to my IPO shares if I sell before the 180-day lock-up expires?
A: You cannot sell shares acquired in an IPO allocation until the lock-up period expires unless you are not subject to lock-up restrictions, which is rare for individual allocations.

Q: How do I calculate my after-tax proceeds if I live in a high-tax state?
A: Add your federal long-term capital gains rate (0%, 15%, or 20%) to your state rate (13.3% in California, 10.9% in New York) and subtract that combined percentage from your gross gain.

Calculate Your After-Tax IPO Exit Value

Use CalcMoney's Calculate Your After-Tax RSU Proceeds to model your net IPO exit value under your exact state tax rate, holding period, and position size.

Run the Numbers: Capital Gains Tax Terminal on CalcMoney — see your exact figures under current market conditions.

Data sourced from SEC EDGAR S-1 Filings (IPO). Rates and thresholds are for informational purposes only. Consult a licensed financial advisor before making mortgage, investment, or tax decisions.

Featured Partner

FIDELITY